Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism

Yong Tao Lv, Yun Zhang, Min Liu, Jia na ti Qiuwaxi, Paul Ashwood, Sungho Charles Cho, Ying Huan, Ru Cun Ge, Xing Wang Chen, Zhao Jing Wang, Byung Jo Kim, Xiang Hu

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism.Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment.Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05).Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.Trial registration: ClinicalTrials.gov: NCT01343511, Title " Safety and Efficacy of Stem Cell Therapy in Patients with Autism" .

Original languageEnglish
Article number196
JournalJournal of Translational Medicine
Volume11
Issue number1
DOIs
Publication statusPublished - 2013 Aug 27

Fingerprint

Umbilical Cord
Autistic Disorder
Stem cells
Mesenchymal Stromal Cells
Fetal Blood
Blood Cells
Blood
Transplantation
Safety
Patient rehabilitation
Therapeutics
Rehabilitation
Cell Transplantation
Checklist
Stem Cells
Mesenchymal Stem Cell Transplantation
Spinal Injections
Control Groups
Stem Cell Transplantation
Therapeutic Uses

Keywords

  • Autism
  • Cell transplantation
  • Cord blood mononuclear cell
  • Umbilical cord-derived mesenchymal stem cell

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. / Lv, Yong Tao; Zhang, Yun; Liu, Min; Qiuwaxi, Jia na ti; Ashwood, Paul; Cho, Sungho Charles; Huan, Ying; Ge, Ru Cun; Chen, Xing Wang; Wang, Zhao Jing; Kim, Byung Jo; Hu, Xiang.

In: Journal of Translational Medicine, Vol. 11, No. 1, 196, 27.08.2013.

Research output: Contribution to journalArticle

Lv, YT, Zhang, Y, Liu, M, Qiuwaxi, JNT, Ashwood, P, Cho, SC, Huan, Y, Ge, RC, Chen, XW, Wang, ZJ, Kim, BJ & Hu, X 2013, 'Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism', Journal of Translational Medicine, vol. 11, no. 1, 196. https://doi.org/10.1186/1479-5876-11-196
Lv, Yong Tao ; Zhang, Yun ; Liu, Min ; Qiuwaxi, Jia na ti ; Ashwood, Paul ; Cho, Sungho Charles ; Huan, Ying ; Ge, Ru Cun ; Chen, Xing Wang ; Wang, Zhao Jing ; Kim, Byung Jo ; Hu, Xiang. / Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. In: Journal of Translational Medicine. 2013 ; Vol. 11, No. 1.
@article{0f217f2ea51545858140e2125c05498e,
title = "Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism",
abstract = "Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism.Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment.Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05).Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.Trial registration: ClinicalTrials.gov: NCT01343511, Title {"} Safety and Efficacy of Stem Cell Therapy in Patients with Autism{"} .",
keywords = "Autism, Cell transplantation, Cord blood mononuclear cell, Umbilical cord-derived mesenchymal stem cell",
author = "Lv, {Yong Tao} and Yun Zhang and Min Liu and Qiuwaxi, {Jia na ti} and Paul Ashwood and Cho, {Sungho Charles} and Ying Huan and Ge, {Ru Cun} and Chen, {Xing Wang} and Wang, {Zhao Jing} and Kim, {Byung Jo} and Xiang Hu",
year = "2013",
month = "8",
day = "27",
doi = "10.1186/1479-5876-11-196",
language = "English",
volume = "11",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism

AU - Lv, Yong Tao

AU - Zhang, Yun

AU - Liu, Min

AU - Qiuwaxi, Jia na ti

AU - Ashwood, Paul

AU - Cho, Sungho Charles

AU - Huan, Ying

AU - Ge, Ru Cun

AU - Chen, Xing Wang

AU - Wang, Zhao Jing

AU - Kim, Byung Jo

AU - Hu, Xiang

PY - 2013/8/27

Y1 - 2013/8/27

N2 - Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism.Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment.Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05).Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.Trial registration: ClinicalTrials.gov: NCT01343511, Title " Safety and Efficacy of Stem Cell Therapy in Patients with Autism" .

AB - Background: Autism is a pervasive neurodevelopmental disorder. At present there are no defined mechanisms of pathogenesis and therapy is mostly limited to behavioral interventions. Stem cell transplantation may offer a unique treatment strategy for autism due to immune and neural dysregulation observed in this disease. This non-randomized, open-label, single center phase I/II trial investigated the safety and efficacy of combined transplantation of human cord blood mononuclear cells (CBMNCs) and umbilical cord-derived mesenchymal stem cells (UCMSCs) in treating children with autism.Methods: 37 subjects diagnosed with autism were enrolled into this study and divided into three groups: CBMNC group (14 subjects, received CBMNC transplantation and rehabilitation therapy), Combination group (9 subjects, received both CBMNC and UCMSC transplantation and rehabilitation therapy), and Control group (14 subjects, received only rehabilitation therapy). Transplantations included four stem cell infusions through intravenous and intrathecal injections once a week. Treatment safety was evaluated with laboratory examinations and clinical assessment of adverse effects. The Childhood Autism Rating Scale (CARS), Clinical Global Impression (CGI) scale and Aberrant Behavior Checklist (ABC) were adopted to assess the therapeutic efficacy at baseline (pre-treatment) and following treatment.Results: There were no significant safety issues related to the treatment and no observed severe adverse effects. Statistically significant differences were shown on CARS, ABC scores and CGI evaluation in the two treatment groups compared to the control at 24 weeks post-treatment (p < 0.05).Conclusions: Transplantation of CBMNCs demonstrated efficacy compared to the control group; however, the combination of CBMNCs and UCMSCs showed larger therapeutic effects than the CBMNC transplantation alone. There were no safety issues noted during infusion and the whole monitoring period.Trial registration: ClinicalTrials.gov: NCT01343511, Title " Safety and Efficacy of Stem Cell Therapy in Patients with Autism" .

KW - Autism

KW - Cell transplantation

KW - Cord blood mononuclear cell

KW - Umbilical cord-derived mesenchymal stem cell

UR - http://www.scopus.com/inward/record.url?scp=84883077674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883077674&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-11-196

DO - 10.1186/1479-5876-11-196

M3 - Article

VL - 11

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 196

ER -